<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CAPECITABINE</span><br/>(cap-e-si'ta-been)<br/><span class="topboxtradename">Xeloda<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antimetabolite, pyrimidine</span><br/><b>Prototype: </b>Fluorouracil (5-FU)<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 mg, 500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Pyrimidine antagonist and cell cycle-specific antimetabolite. Prodrug of 5-FU. Blocks actions of enzymes essential to normal
         DNA and RNA synthesis. May become incorporated into RNA molecules thereby interfering with RNA and protein synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces or stabilizes tumor size in metastatic breast cancer.</p>
<h1><a name="uses">Uses</a></h1>
<p>Metastatic breast cancer refractory to other treatments, colorectal cancer, single-agent adjuvant therapy for colon cancer
         after surgery.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to capecitabine, doxifluridine, 5-FU; myelosuppression; dihydropyrimidine dehydrogenase (DPD) deficiency;
         females of childbearing age; active infection; jaundice; severe renal failure or impairment; pregnancy (category D); lactation,
         children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Mild to moderate renal or hepatic dysfunction; bacterial or viral infection; coronary artery disease, angina, cardiac arrhythmias;
         history of varicella zoster or other herpes infections; older adults.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Breast Cancer, Colorectal Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2500 mg/m<sup>2</sup>/d in 2 divided doses times 2 wk, then 1 wk off. Repeat<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 3050 mL/min reduce dose by 25%, <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Morning and evening doses (about 12 h apart) should be given within 30 min of the end of a meal. Water is the preferred liquid
            for taking this drug.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Fatigue,</span> pyrexia, pain, myalgia. <span class="typehead">CV:</span> Edema. <span class="typehead">GI:</span>
<span class="speceff-common">Severe diarrhea, nausea, vomiting, stomatitis,</span> abdominal pain, constipation, dyspepsia, <span class="speceff-common">anorexia.</span>
<span class="typehead">Hematologic:</span>
<i>
<u>Neutropenia, thrombocytopenia</u>, <u>anemia, lymphopenia</u>
</i>. <span class="typehead">Metabolic:</span> Dehydration, <span class="speceff-life">hyperbilirubinemia</span>. <span class="typehead">CNS:</span> Paresthesias, headache, dizziness, insomnia. <span class="typehead">Skin:</span>
<span class="speceff-life">Hand-and-foot syndrome</span>, <span class="speceff-common">dermatitis</span>, nail disorder. <span class="typehead">Special Senses:</span> Eye irritation. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Leucovorin</b> increases concentration and toxicity of <b>5-FU,</b> altered coagulation and/or bleeding reported with <b>warfarin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Absorption significantly reduced by food. <span class="typehead">Peak:</span> 1.52 h. <span class="typehead">Distribution:</span> Approx 35% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized to 5-FU. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 45 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor periodically CBC with differential and liver functions including bilirubin, transaminases, alkaline phosphatase.</li>
<li>Monitor carefully for S&amp;S of grade 2 or greater toxicity: diarrhea &gt;4 BMs/day or at night; vomiting &gt;1 time/24 h; significant
            loss of appetite or anorexia; stomatitis; hand-and-foot syndrome (pain, swelling, erythema, desquamation, blistering); temperature
            = 100.5° F; and S&amp;S of infection.
         </li>
<li>Withhold drug and immediately report S&amp;S of grade 2 or greater toxicity.</li>
<li>Monitor for dehydration and replace fluids as needed.</li>
<li>Monitor carefully patients with coronary artery disease for S&amp;S of cardiotoxicity (e.g., increasing angina).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately significant nausea, loss of appetite, diarrhea, soreness of tongue, fever of 100.5° F or more, or
            signs of infection. Review patient drug package insert carefully for more detail.
         </li>
<li>Inform physician immediately if you become pregnant.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>